Abdelsalam et al., 2022 [53] identified two compounds (compounds 3b and 3d) (Figure 3) in this series showing notable anti-NSCLC activity, inhibiting EGFR at nanomolar levels. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.